Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/172402
Title: Syndrome and outcome of antibody-negative limbic encephalitis
Author: Graus Ribas, Francesc
Escudero, Domingo
Oleaga Zufiría, Laura
Bruna, Jordi
Villarejo Galende, Alberto
Ballabriga, Jordi
Barceló, María Inés
Gilo, Francisco
Popkirov, Stoyan
Stourac, Pavel
Dalmau Obrador, Josep
Keywords: Encefalitis
Autoimmunitat
Encephalitis
Autoimmunity
Issue Date: 1-Aug-2018
Publisher: Wiley
Abstract: Background and purpose: The aim was to report the clinical characteristics of 12 patients with limbic encephalitis (LE) who were antibody‐negative after a comprehensive immunological study. Methods: The clinical records of 163 patients with LE were reviewed. Immunohistochemistry on rat brain, cultured neurons and cell‐based assays were used to identify neuronal autoantibodies. Patients were included if (i) there was adequate clinical, cerebrospinal fluid (CSF) and magnetic resonance imaging information to classify the syndrome as LE, (ii) magnetic resonance images were accessible for central review and (iii) serum and CSF were available and were confirmed negative for neuronal antibodies. Results: Twelve (7%) of 163 LE patients [median age 62 years; range 40-79; 9 (75%) male] without neuronal autoantibodies were identified. The most frequent initial complaints were deficits in short‐term memory leading to hospital admission in a few weeks (median time 2 weeks; range 0.5-12). In four patients the short‐term memory dysfunction remained as an isolated symptom during the entire course of the disease. Seizures, drowsiness and psychiatric problems were unusual. Four patients had solid tumors (one lung, one esophagus, two metastatic cervical adenopathies of unknown primary tumor) and one chronic lymphocytic leukemia. CSF showed pleocytosis in seven (58%) with a median of 13 white blood cells/mm3 (range 9-25). Immunotherapy included corticosteroids, intravenous immunoglobulins and combinations of both drugs or with rituximab. Clinical improvement occurred in six (54%) of 11 assessable patients. Conclusions: Despite the discovery of new antibodies, 7% of LE patients remain seronegative. Antibody‐negative LE is more frequent in older males and usually develops with predominant or isolated short‐term memory loss. Despite the absence of antibodies, patients may have an underlying cancer and respond to immunotherapy.
Note: Versió postprint del document publicat a: https://doi.org/10.1111/ene.13661
It is part of: European Journal of Neurology, 2018, vol. 25, num. 8, p. 1011-1016
URI: http://hdl.handle.net/2445/172402
Related resource: https://doi.org/10.1111/ene.13661
ISSN: 1351-5101
Appears in Collections:Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
698011.pdf604.83 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.